The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports
Innoviva Buys Remaining Shares in Advanced Antibiotic Co.
Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share.H2/22 Slated to Be Catalyst Rich for Pharma Co.
Research Report
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that their newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs.
New Improved Drug Expected to Get FDA Approval Next Month
Research Report
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.
US Pharma Co. Granted FDA Approval for IV Smallpox Drug
SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox.Firm Reports Encouraging Trial Results in Cystinosis
Research Report
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.
EU Co. Secures Smallpox Vaccine Order to Target Monkeypox
Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox.Coverage Launched on Co. in Alzheimer's Drug Space
Research Report
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.
Clinical Catalysts for Biotech's Stock On Track for Mid 2022
Research Report
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.
Biopharma Co. to Launch Two Clinical Trials This Year
Research Report
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.
Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer.First Results From Biotech Co.'s Lymphoma Program Are Impressive
Research Report
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.
Pfizer Offers $11.6B to Buy Biopharma Co.
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities.Biopharma Co. Licenses Orphan Drug to UK Firm for $450M
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver.Analyst Says Avivagen Is a Strong Buy
Contributed Opinion
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy.
Pilot Launch of VLN Cigarettes in Progress
Research Report
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.
Biotech Co. Advances COVID-19 Vaccines Toward Approval
Research Report
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.
Could a New Prescription Drug Treat This Common Ailment?
Research Report
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.
Biopharma Co. Posts 32% YoY Gain in Proprietary Sales
Alkermes Plc. shares traded 12% higher after the Ireland-based company reported Q1/22 financial results and reiterated its FY/22 business outlook.Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials
Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies.FDA Grants RMAT Status for T-Cell Therapy for Six Viruses
Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients.Biotech Co.'s Shares Quadruple on $250M Buyout Bid
Shares of Checkmate Pharmaceuticals Inc. traded 330% higher to a new 52-week high after the company reported it agreed to be acquired by Regeneron Pharmaceuticals Inc. for $10.50 per share in cash.Senior Biotech Analyst's Top 3 Stocks
Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs.Life Sciences Co. Expected to Attract Partners, Big Pharma
Research Report
"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases.
Vaccine Maker Awarded Approval for COVID-19 Vaccine
Shares of Valneva SE traded 8.5% higher after the company reported that the U.K.'s MHRA has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate called VLA2001 for primary immunization in adults between 18 and 50 years old.GSK Offers $1.9B for Cancer-Focused Pharma Co.
Shares of Sierra Oncology Inc. traded 38% higher after the company reported it agreed to be acquired by GlaxoSmithKline Plc. for $55 per share in cash.Showing Results: 1 to 25 of 109 Next